1925. Prevalence of SARS-CoV-2 Infection in Immunocompromised Patients Following Receipt of Tixagevimab/Cilgavimab. (15th December 2022)

• Record Type: Journal Article
• Authors: Lim, Sarah; Morris, Keeley; Fess, Lydia J; Como-Sabetti, Kathy; Lynfield, Ruth
• Is Part Of: Open forum infectious diseases. Volume 9:(2022)Supplement 2
• Publication Date: 2022-12-15
• Subjects: Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofac492.1552
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Background: Tixagevimab/cilgavimab (TC) was approved by the FDA in December 2021 for use as pre-exposure prophylaxis in patients with moderate to severe immune compromise. On February 24, FDA recommended a second dose for patients who received the original dosing because of decreased activity against Omicron subvariants. We were interested in reviewing TC experience in Minnesota. Methods: Minnesota Department of Health established a voluntary TC patient registry in December 2021, including date of treatment, COVID-19 vaccination status and immunocompromising conditions. Patients were matched to state COVID-19 case data from December 1, 2021 to April 22, 2022, to examine occurrence of SARS-CoV-2 infection (a positive test by PCR or antigen) following receipt of TC. Results: Data were available for 289 patients, representing 5-10% of all patients treated with TC in Minnesota. 53% were male with a median age of 62 (IQR 48-70). 13 patients (4.5%) had not received COVID-19 vaccine at the time of initial TC dose. 128 patients (44%) received 2 doses of TC. Immunocompromising conditions included: hematological malignancy (114, 39.4%), treatment with immunosuppressant medications (113, 39.1%), solid organ transplant (45, 15.6%), and stem cell transplant (13, 4.5%). 5 patients (1.7%) had a positive SARS-CoV-2 test (4 PCR, 1 antigen) following receipt of TC (Table 1); patients tested positive on days 7, 11, 13, 17 and 48/70. Three patients were on rituximab and 2 had hematological malignancy. All 5 had received 3 doses of COVID-19 vaccine prior to receipt of TC. Variant information was available for 2 patients: BA.1 and BA.1.1. 1 patient required hospitalization for COVID-19 and died 39 days after the positive test but had 3 subsequent negative tests before discharge; death was attributed to underlying malignancy. Table 1: Characteristics of patients with positive SARS-CoV-2 tests following treatment with tixagevimab/cilgavimab. Conclusion: In a convenience sample of 289 patients who received TC, 5 patients had COVID-19, with 3 occurring within the SARS CoV-2 incubation period following receipt of TC. One of the other patients was positive after receiving 2 doses of TC. Following effectiveness of TC will be useful as SARS CoV-2 continues to evolve. Disclosures: All Authors : No reported disclosures.